DK0813873T3 - Farmaceutisk sammensætning omfattende mirtazapin og en eller flere selektive serotingenoptagelseshæmmere - Google Patents

Farmaceutisk sammensætning omfattende mirtazapin og en eller flere selektive serotingenoptagelseshæmmere

Info

Publication number
DK0813873T3
DK0813873T3 DK97201853T DK97201853T DK0813873T3 DK 0813873 T3 DK0813873 T3 DK 0813873T3 DK 97201853 T DK97201853 T DK 97201853T DK 97201853 T DK97201853 T DK 97201853T DK 0813873 T3 DK0813873 T3 DK 0813873T3
Authority
DK
Denmark
Prior art keywords
serotin
mirtazapine
selective
pharmaceutical composition
reuptake inhibitors
Prior art date
Application number
DK97201853T
Other languages
Danish (da)
English (en)
Inventor
Victor Johannes Nickolson
Original Assignee
Akzo Nobel Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8224094&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0813873(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Akzo Nobel Nv filed Critical Akzo Nobel Nv
Application granted granted Critical
Publication of DK0813873T3 publication Critical patent/DK0813873T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK97201853T 1996-06-19 1997-06-17 Farmaceutisk sammensætning omfattende mirtazapin og en eller flere selektive serotingenoptagelseshæmmere DK0813873T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP96201703 1996-06-19

Publications (1)

Publication Number Publication Date
DK0813873T3 true DK0813873T3 (da) 2002-05-27

Family

ID=8224094

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97201853T DK0813873T3 (da) 1996-06-19 1997-06-17 Farmaceutisk sammensætning omfattende mirtazapin og en eller flere selektive serotingenoptagelseshæmmere

Country Status (24)

Country Link
US (1) US5977099A (cs)
JP (2) JP4925074B2 (cs)
KR (1) KR100481254B1 (cs)
CN (1) CN1132581C (cs)
AR (1) AR007609A1 (cs)
AT (1) ATE213159T1 (cs)
AU (1) AU727851B2 (cs)
BR (1) BR9703624A (cs)
CA (1) CA2208199C (cs)
CZ (1) CZ290691B6 (cs)
DE (1) DE69710390T2 (cs)
DK (1) DK0813873T3 (cs)
ES (1) ES2172744T3 (cs)
HU (1) HU225534B1 (cs)
ID (1) ID17051A (cs)
IL (1) IL121076A (cs)
NO (1) NO313177B1 (cs)
NZ (1) NZ328113A (cs)
PL (1) PL188520B1 (cs)
PT (1) PT813873E (cs)
RU (1) RU2181287C2 (cs)
SG (1) SG60073A1 (cs)
TR (1) TR199700522A2 (cs)
ZA (1) ZA975335B (cs)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL121076A (en) * 1996-06-19 2000-10-31 Akzo Nobel Nv Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
TR200001293T2 (tr) * 1997-11-14 2002-09-23 Akzo Nobel N.V. Uykuda solunum durmasını tedavi etmek için mirtazapin kullanımı
US6960577B2 (en) * 1998-05-22 2005-11-01 Eli Lilly And Company Combination therapy for treatment of refractory depression
US6727283B2 (en) 1998-10-13 2004-04-27 Pfizer Inc. Sertraline oral concentrate
US6575147B2 (en) * 1999-02-25 2003-06-10 Go-Tec Internal combustion system adapted for use of a dual fuel composition including acetylene
US6545149B2 (en) 1999-04-19 2003-04-08 Teva Pharmaceutical Industries Ltd. Synthesis and crystallization of piperazine ring-containing compounds
EP1178805A4 (en) * 1999-04-19 2004-11-24 Teva Pharma NOVEL SYNTHESIS AND CRYSTALLIZATION OF PIPERAZINE-CONTAINING COMPOUNDS
US6403657B1 (en) * 1999-10-04 2002-06-11 Martin C. Hinz Comprehensive pharmacologic therapy for treatment of obesity
US6759437B2 (en) * 1999-10-04 2004-07-06 Martin C. Hinz Comprehensive pharmacologic therapy for treatment of obesity including cysteine
TWI256309B (en) * 1999-10-13 2006-06-11 Akzo Nobel Nv New formulation of mirtazapine
HUP0204050A3 (en) * 2000-01-19 2004-09-28 Akzo Nobel Nv Drug combination for the treatment of depression and related disorders comprising mirtazapine and gepirone
CN1395487A (zh) * 2000-02-11 2003-02-05 阿克佐诺贝尔公司 米氮平用于治疗睡眠障碍的用途
AU2002212888A1 (en) * 2000-11-01 2002-05-15 Respiratorius Ab Composition comprising: serotonin receptor antagonists (5ht-2, 5ht-3) and agonist (5ht-4)
JP2004532190A (ja) * 2001-02-12 2004-10-21 アクゾ・ノベル・エヌ・ベー アポリポタンパク質ｅ４の遺伝子の遺伝子型決定により大うつ病の治療を改善するための方法
US20030105082A1 (en) * 2001-12-03 2003-06-05 Murphy Greer Marechal Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
US6399310B1 (en) 2001-02-12 2002-06-04 Akzo Nobel N.V. Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
US20070293571A1 (en) * 2006-06-08 2007-12-20 Hinz Martin C Adminstration of dopa precursors with sources of dopa to effectuate optimal catecholamine neurotransmitter outcomes
US20090311795A1 (en) * 2002-03-21 2009-12-17 Hinz Martin C Bilateral control of functions traditionally regulated by only serotonin or only dopamine
BR0308556A (pt) * 2002-03-21 2005-05-03 Martin C Hinnz Tecnologia de otimização do segmento de sistema de serotonina e de catecolaminas
AU2003274608A1 (en) * 2002-11-07 2004-06-07 Sunil Sadanand Nadkarni Process for preparation of polymorphic form of sertraline hydrochloride
AR042806A1 (es) 2002-12-27 2005-07-06 Otsuka Pharma Co Ltd Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
DE60317098T2 (de) 2002-12-27 2008-08-07 Otsuka Pharmaceutical Co., Ltd. Carbostyril-derivate mit selektiven serotonin-aufnahmeinhibitoren zur behandlung von gemütskrankheiten
CA2516653A1 (en) * 2003-02-21 2004-09-10 Martin C. Hinz Serotonin and catecholamine system segment optimization technology
TW200502222A (en) * 2003-04-02 2005-01-16 Novartis Ag Use of 10-hydroxy-10,11-dihydrocarbamazepine derivatives for the treatment of affective disorders
ATE388698T1 (de) 2003-04-29 2008-03-15 Orexigen Therapeutics Inc Zusammensetzungen zur beeinflussung des gewichtsverlusts
US20050234093A1 (en) * 2003-06-25 2005-10-20 H. Lundbeck A/S Treatment of depression and other affective disorders
US7838029B1 (en) 2003-07-31 2010-11-23 Watson Laboratories, Inc. Mirtazapine solid dosage forms
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
EP1667972B1 (en) 2003-09-10 2013-06-19 Brentwood Equities Ltd. Diastereomers of 4-aryloxy-3-hydroxypiperidines
US7713959B2 (en) * 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
TW200538100A (en) * 2004-04-21 2005-12-01 Akzo Nobel Nv Mirtazapine salts
WO2006023703A2 (en) * 2004-08-20 2006-03-02 Cypress Bioscience, Inc. Method for treating sleep related breathing disorders
RU2283097C2 (ru) * 2004-11-16 2006-09-10 Эльвира Ивановна Белобородова Способ лечения бронхиальной астмы, сочетанной с эрозивно-язвенными поражениями гастродуоденальной зоны
EP1827450A4 (en) * 2004-11-17 2009-04-22 Cypress Bioscience Inc METHOD FOR REDUCING THE SIDE EFFECTS OF TREATMENT WITH MIRTAZAPINE
BRPI0517847A (pt) * 2004-11-19 2008-10-21 Organon Nv combinação, usos de um inibidor de reabsorção de serotonina seletiva e de um antagonista do receptor de glicocorticóide, e, método para o tratamento de um indivìduo de uma espécie vertebrada sofrendo de depressão ou um distúrbio relacionado
PT2135603E (pt) 2005-11-22 2013-04-03 Orexigen Therapeutics Inc Composições e métodos para aumentar a sensibilidade à insulina
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
MX2009004874A (es) 2006-11-09 2009-06-16 Orexigen Therapeutics Inc Formulaciones farmaceuticas estratificadas que comprenden una capa intermediaria que se disuelve rapidamente.
MX343867B (es) 2006-11-09 2016-11-25 Orexigen Therapeutics Inc Paquete de dosificacion unitaria y metodos para administrar medicaciones de perdida de peso.
EP2167096A4 (en) * 2007-06-13 2010-07-14 Cypress Bioscience Inc IMPROVING TOLERANCE TO MIRTAZAPINE AND A SECOND ACTIVE INGREDIENT BY THE COMBINED USE OF THEM
CN101332193B (zh) * 2007-06-29 2012-12-12 杭州民生药业有限公司 一种马来酸氟伏沙明药物组合物的制备方法
US20110144145A1 (en) 2008-05-30 2011-06-16 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
CN102459769B (zh) 2009-06-09 2014-03-26 住友重机械工业株式会社 混合式挖土机及其控制方法
WO2011059207A2 (en) * 2009-11-13 2011-05-19 Green Cross Corporation Arylpiperazine-containing purine derivatives and uses thereof
MX383154B (es) 2010-01-11 2025-03-13 Nalpropion Pharmaceuticals Llc Usos de naltrexona y bupoprion para tratar depresión mayor.
CN102000334B (zh) * 2010-10-15 2012-02-22 北京大学 用于治疗抑郁症的复方制剂
RU2475235C2 (ru) * 2011-03-15 2013-02-20 Общество с ограниченной ответственностью "ЭР ЭНД ДИ ФАРМА" Фармацевтическая композиция для профилактики и лечения депрессивных состояний
TWI636784B (zh) * 2011-04-05 2018-10-01 大塚製藥股份有限公司 含7-〔4-(4-苯並〔b〕噻吩-4-基-哌-1-基)丁氧基〕-1H-喹啉-2-酮之醫藥組成物與套組，以及彼之用途
PL3730132T3 (pl) 2012-06-06 2022-10-10 Nalpropion Pharmaceuticals Llc Kompozycja do zastosowania w sposobie leczenia nadwagi i otyłości u pacjentów z wysokim ryzykiem sercowo-naczyniowym

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL189199C (nl) * 1975-04-05 1993-02-01 Akzo Nv Werkwijze ter bereiding van farmaceutische preparaten met werking op het centraal zenuwstelsel op basis van benz(aryl)azepinederivaten, de verkregen gevormde farmaceutische preparaten, alsmede werkwijze ter bereiding van de toe te passen benz(aryl)azepinederivaten.
AU8770282A (en) * 1981-08-27 1983-03-03 Shaun R. Coughlin Composition for the treatment of atherosclerosis
US4940585A (en) * 1989-02-17 1990-07-10 Hapworth William E Method for the treatment of nicotine withdrawal syndrome
ES2062310T3 (es) * 1989-12-06 1994-12-16 Akzo Nv Un procedimiento para fabricar un preparado farmaceutico acuoso estabilizado.
US5208261A (en) * 1989-12-06 1993-05-04 Akzo N.V. Stabilized solutions of psychotropic agents
IE63986B1 (en) * 1989-12-30 1995-06-28 Akzo Nv Pharmaceutical preparation for oral administration in fluid form
US5512593A (en) * 1993-03-02 1996-04-30 John S. Nagle Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor
IL121076A (en) * 1996-06-19 2000-10-31 Akzo Nobel Nv Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
TW587938B (en) * 1997-03-27 2004-05-21 Akzo Nobel Nv Pharmaceutical composition for the treatment and/or prophylaxis of psychotic disorder
AU750808B2 (en) * 1997-10-03 2002-07-25 Cary Medical Corporation Compositon for the treatment of nicotine addiction containing a nicotine receptor antagonist and an anti-depressant or anti-anxiety drug

Also Published As

Publication number Publication date
TR199700522A3 (tr) 1998-01-21
RU2181287C2 (ru) 2002-04-20
CZ187097A3 (cs) 1998-01-14
ATE213159T1 (de) 2002-02-15
ID17051A (id) 1997-12-04
CA2208199C (en) 2006-10-24
PL188520B1 (pl) 2005-02-28
KR980000447A (ko) 1998-03-30
NZ328113A (en) 1999-09-29
HUP9701068A3 (en) 2000-07-28
CN1173330A (zh) 1998-02-18
NO972816L (no) 1997-12-22
ES2172744T3 (es) 2002-10-01
AU727851B2 (en) 2001-01-04
JP4925074B2 (ja) 2012-04-25
JPH1067663A (ja) 1998-03-10
HU225534B1 (en) 2007-02-28
IL121076A0 (en) 1997-11-20
HUP9701068A2 (hu) 1998-08-28
MX9704579A (es) 1998-07-31
TR199700522A2 (xx) 1998-01-21
DE69710390D1 (de) 2002-03-21
AU2612997A (en) 1998-01-08
AR007609A1 (es) 1999-11-10
HU9701068D0 (en) 1997-08-28
JP2009137970A (ja) 2009-06-25
SG60073A1 (en) 1999-02-22
ZA975335B (en) 1998-01-26
HK1006081A1 (en) 1999-02-12
PL320628A1 (en) 1997-12-22
NO313177B1 (no) 2002-08-26
PT813873E (pt) 2002-06-28
NO972816D0 (no) 1997-06-18
CA2208199A1 (en) 1997-12-19
BR9703624A (pt) 1998-09-01
DE69710390T2 (de) 2002-08-14
IL121076A (en) 2000-10-31
CZ290691B6 (cs) 2002-09-11
CN1132581C (zh) 2003-12-31
KR100481254B1 (ko) 2005-09-12
US5977099A (en) 1999-11-02

Similar Documents

Publication Publication Date Title
DK0813873T3 (da) Farmaceutisk sammensætning omfattende mirtazapin og en eller flere selektive serotingenoptagelseshæmmere
DK1112174T3 (da) Isosorbidholdige polyestere og fremgangsmåder til fremstiling heraf
NO20002359L (no) Adenosinderivater og farmasoytisk sammensetning inneholdende derivatene
NO20002849D0 (no) Sammensetninger og metoder for Õ indusere genekspersjon
NO984354D0 (no) Avisingsmiddel og anvendelse av dette
NO20001323D0 (no) Dipeptid-apoptose inhibitorer og deres anvendelse
NO20006488D0 (no) Sammensetning og anvendelse
DK1112003T3 (da) Ny sammensætning og anvendelse
NO20011157L (no) Benzenderivater og farmasöytisk anvendelse derav
DK0804078T3 (da) Sammensætning og anvendelse deraf
PT956294E (pt) Inibidores da trombina
NO995513D0 (no) N-triazolyl-2-indolkarboksamider og deres anvendelse som CCK-A agonister
DK1068238T3 (da) Integrinheterodimer og subunit deraf
DK0910369T3 (da) Benzothiophener, formuleringer indeholdende samme og fremgangsmåder
NO983802D0 (no) Benzothiofener, formuleringer inneholdende samme og fremgangsmÕter
NO20003142L (no) Substituerte isokinolin-derivater og anvendelse derav som antikrampemidler
DK1066261T3 (da) Pyridinderivat og farmaceutisk præparat indeholdende samme
NO991749D0 (no) Sammensetninger til bruk i betong og betongprodukter fremstilt derav
DK1061955T3 (da) Polynukleotidsammensætning, fremstillingsmetode og anvendelse deraf
NO20003268L (no) Hyperhydrert kitikolin, fremgangsmÕte og anvendelse
PT948483E (pt) Inibidores da farnesil-transferase
NO984921D0 (no) Tienopyridinderivater og deres anvendelse
NO983556L (no) Formulering og anvendelse
NO306613B1 (no) Oligomer og farmasöytisk preparat omfattende denne
NO20015519D0 (no) Farmasöytisk sammensetning omfattende apokodein og/eller dets derivater